Establishment Labs Holdings INC 10-Q quarterly reports

Establishment Labs Holdings Inc. announced a 37.5% year-over-year revenue increase for the first six months of 2026, driven by strong U.S. market performance, while also managing to improve gross margins.

Establishment Labs reported a 44.7% revenue increase to $59.9 million for Q1 2026, driven by strong U.S. market adoption of Motiva Implants.

Establishment Labs Holdings Inc. reported a 33.8% increase in Q3 revenue, driven by strong U.S. market penetration and improved gross margins, despite an increase in nine-month operating losses.

Establishment Labs Holdings Inc. reported increased revenue driven by U.S. market entry but saw wider net losses and significant cash burn in the second quarter of 2025.

Establishment Labs saw an 11.3% increase in revenue for the first quarter of 2025, fueled by strong U.S. sales following FDA approval of Motiva Implants.

Establishment Labs reported a decrease in revenue for the nine months ended September 30, 2024, alongside a net loss, while highlighting FDA approval for Motiva Implants and a new manufacturing facility.

Establishment Labs' Q2 2024 results show a revenue decrease of 9.3% compared to Q2 2023, alongside a net loss, while the company completed an FDA inspection of its Costa Rica facility.

Establishment Labs reported a decrease in revenue for the first quarter of 2024, alongside a net loss, as the company navigates a challenging macroeconomic environment.